Search Result

CRISPR Therapeutics

In 2018, ViaCyte formed a collaboration with CRISPR Therapeutics, a leading company in the gene-editing space focused on developing transformative medicines for serious human diseases. ViaCyte and CRISPR are collaborating on an exciting project to discover, develop, and commercialize gene-edited allogeneic stem cell-derived therapies for the treatment of diabetes. Together we are seeking to develop an immune-evasive stem cell line, derived from our well-characterized, regulatory compliant CyT49 line, as a first step on the path to a stem cell-derived product that can be used off-the-shelf without immune suppression.

Read More